David Berd

AXYS Technologies (Canada) — Canada

Immunology and Microbiology · Life Sciences

44h-index5.5kcitations156works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(80), Cancer Immunotherapy and Biomarkers(31), Monoclonal and Polyclonal Antibodies Research(22), CAR-T cell therapy research(22), Cutaneous Melanoma Detection and Management(20)

Publications156 total

Portrait of an autologous cancer vaccine: Then and now
Human Vaccines & Immunotherapeutics·2023· 8 citedOpen Access
Double-Blinded, Randomized Phase II Study Using Embolization with or without Granulocyte–Macrophage Colony-Stimulating Factor in Uveal Melanoma with Hepatic Metastases
Journal of Vascular and Interventional Radiology·2015· 88 citedOpen Access
Autologous ovarian tumor cells vaccine, modified with the hapten, dinitrophenyl (DNP), in platinum resistant ovarian cancer
Gynecologic Oncology·2014· 2 cited
A tale of two pities
Human Vaccines & Immunotherapeutics·2012· 8 citedOpen Access
Interleukin 6 mediates production of interleukin 10 in metastatic melanoma
Cancer Immunology Immunotherapy·2011· 36 citedOpen Access
Lymph node ratio is an important and independent prognostic factor for patients with stage III melanoma
Journal of Surgical Oncology·2011· 15 cited
Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine
Cancer Immunology Immunotherapy·2011· 24 citedOpen Access
Abstract 1802: Genomic changes elicited by mitomycin C that confer increased sensitivity of peritoneal cancer cells to death ligands
Cancer Research·2011
Interleukin-10 as a prognostic factor in patients treated with autologous melanoma cell vaccine.
Journal of Clinical Oncology·2010
Abstract 4755: Importance of an induction dose to the immunogenicity of cancer vaccines: A reverse translational study
Cancer Research·2010
High-Dose Immunoembolization: Survival Benefit in Patients with Hepatic Metastases from Uveal Melanoma
Radiology·2009· 65 citedOpen Access
QS333. Lymph Node Ratio Is an Important and Independent Prognostic Factor for Patients With Stage III Malignant Melanoma
Journal of Surgical Research·2009
Human interleukin 10 receptor 1/IgG1-Fc fusion proteins: immunoadhesins for human IL-10 with therapeutic potential
Cancer Immunology Immunotherapy·2009· 21 citedOpen Access
Immunoembolization of Malignant Liver Tumors, Including Uveal Melanoma, Using Granulocyte-Macrophage Colony-Stimulating Factor
Journal of Clinical Oncology·2008· 86 citedOpen Access
Dose-response study of a cryopreserved, autologous, hapten-modified melanoma vaccine (Mvax)
Journal of Clinical Oncology·2008· 1 cited
A pilot study of low-dose thalidomide and interferon α-2b in patients with metastatic melanoma who failed prior treatment
Melanoma Research·2007· 20 cited
Prognostic factors for survival after embolization of hepatic metastases in uveal melanoma
Journal of Clinical Oncology·2007· 1 cited
Whipsaw Cancer Treatments: The Role of Hormesis in Endocrine and Immune Therapies
Seminars in Oncology·2006· 5 cited
Treatment of Melanoma with an Autologous, Hapten-Modified Vaccine
Oncología (Barcelona)·2006Open Access
Calculation of Survival of Patients With Stage III Melanoma
Journal of Clinical Oncology·2005· 10 citedOpen Access
page 1 of 8Next →

Frequent Co-authors

Michael J. Mastrangelo(35), Henry Maguire(13), Takami Sato(10), Carol L. Shields(7), Jerry A. Shields(6), Robert E. Bellet(5), Peter A. McCue(4), Kevin L. Sullivan(4), Mizue Terai(4), Gëorge F. Murphy(4), Faith E. Nathan(3), Edmund C. Lattime(3), David J. Eschelman(3), Carin F. Gonsalves(3), Inna Chervoneva(3), Akira Yamamoto(3), Masataka Ohta(2), Hirokazu Nagai(2), John C. Kairys(2), M Wahl(2)